Effective revascularization of the patient with peripheral artery disease is about more than
the procedure. The approach to the patient with symptom-limiting intermittent claudication or …

The prevalence of peripheral artery disease (PAD) continues to increase worldwide. It is
important to identify patients with PAD because of the increased risk of myocardial infarction …

The European Society of Vascular Medicine (ESVM) was founded in Paris in 2012 as a
confederation of already existing and emerging European societies of vascular medicine. At …

Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

Cardiovascular diseases (CVDs) are the leading cause of death and disability in Europe,
posing a great social and economic burden. Coronary artery disease (CAD) is the cause of …

Background—Randomized controlled trials have reported favorable 1-year outcomes with
drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease …

Background: Evidence from large, randomized, controlled peripheral artery disease trials
reporting long-term outcomes using drug-coated balloons (DCBs) is limited. Previously, the …

Lower extremity atherosclerotic peripheral artery disease (PAD) has a very high prevalence
in most nations and in the United States. 1–8 Lower extremity PAD is now known to be …

Objectives: The hypothesis that endovascular treatment with covered stents has equal risks
but higher efficacy than bare-metal stents (BMS) in long femoropopliteal artery disease was …

Cardiovascular disease (CVD) has emerged as a severe illness worldwide. Currently, the
top ten causes of death in the world include ischemic heart disease according to the Global …